Drug intelligence / Profile preview

SBRX7

Development stage: Unknown
Lead developer: Stramsen Biotech

Overview

SBRX7 is a plant-based drug candidate developed by Stramsen Biotech for the treatment of gastrointestinal conditions, including ulcers, heartburn, and dyspepsia (indigestion). Developed by the Texas-based biotech company Stramsen Biotech, SBRX7 is part of a pipeline of botanical medicines. It is reported to be among several candidates in early-stage clinical development. While the specific phytochemical composition and molecular targets remain proprietary, the candidate is designed to provide a plant-derived therapeutic option for common gastric ailments.

Beyond the preview

Go deeper on SBRX7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBRX7.

Explore the full profile